20.20
price up icon0.40%   0.08
after-market 시간 외 거래: 20.20
loading

왜 Newamsterdam Pharma Company Nv (NAMS) 주가가 하락하고 있습니까?

2024-11-20 거래 세션 동안 Newamsterdam Pharma Company Nv(NAMS) 주식이 15.50% 하락한 것을 확인했습니다. 이는 정상적인 변동성이나 다양한 내부 및 외부 요인에 의한 것일 수 있지만, 상황을 적극적으로 모니터링하고 있으며 최대한 빨리 적시에 업데이트를 제공하도록 하겠습니다!
2023-10-23:

Shares of Newamsterdam Pharma Company (NAMS) dropped by 10.07% from $7.05 to $6.34 in the trading on Monday, October 23, 2023. The reason why NAMS stock down is due to a change in the management board. On Monday, Newamsterdam Pharma announced the appointment of Ian Somaiya as its Chief Financial Officer. Mr. Somaiya boasts over twenty-five years of experience in senior leadership roles within the biopharmaceutical industry. Notably, during his 20-year tenure on Wall Street, he gained recognition as a highly regarded industry equity analyst, conducting extensive research on over 100 biotechnology companies across various therapeutic areas, technology platforms, and development stages. His research earned him the distinction of Best on the Street by The Wall Street Journal for multiple consecutive years. Ian Somaiya holds a B.A. in Biology and Neuroscience from New York University. However, despite his impressive credentials, investors reacted cautiously to this news, leading to a decline in the stock's price.

$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
자본화:     |  볼륨(24시간):